{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
dactinomycin
to a specific field?
There is one exact (name or code) match for dactinomycin
Status:
US Approved Rx
(2017)
Source:
ANDA203385
(2017)
Source URL:
First approved in 1964
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Dactinomycin (actinomycin D) was isolated from Streptomyces by Selman Waksman in 1940s. The antibiotic shows anti-cancer activity; it was approved by FDA for the treatment of different cancer conditions among which are Ewing's sarcoma, Wilm's tumor, gestational trophoblastic disease, etc. Dactinomycin exerts its action by binding to DNA (preferably to GC motif) and thus inhibiting transcription.
Showing 1 - 5 of 5 results
Status:
US Approved Rx
(2017)
Source:
ANDA203385
(2017)
Source URL:
First approved in 1964
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Dactinomycin (actinomycin D) was isolated from Streptomyces by Selman Waksman in 1940s. The antibiotic shows anti-cancer activity; it was approved by FDA for the treatment of different cancer conditions among which are Ewing's sarcoma, Wilm's tumor, gestational trophoblastic disease, etc. Dactinomycin exerts its action by binding to DNA (preferably to GC motif) and thus inhibiting transcription.
Status:
Possibly Marketed Outside US
Source:
Octaplasma by Octapharma Pharmazeutika Produktionsges M B H [Canada]
Source URL:
First approved in 2013
Source:
BLA125416
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Class:
MIXTURE
Actinomycin C is an antibiotic complex composed of actinomycin C1, C2 and C3 and produced by Streptomyces chrysomallus.
Actinomycin C reversibly binds to DNA, interfering with the synthesis of RNA, prevention of RNA polymerase elongation and, consequently, with protein synthesis. Actinomycin C exert an inhibitory effect on gram-positive and gram-negative bacteria and on some fungi. However, the toxic properties of the Actinomycin C in relation to antibacterial activity is such as to preclude its use as antibiotics in the treatment of infectious diseases. Because Actinomycin C is cytotoxic, it has an antineoplastic effect which has been demonstrated in experimental animals with various types of tumor implant. This cytotoxic action is the basis for its use in the treatment of certain types of cancer.
